Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066178 · ClinicalTrials.gov registry record · NA
Speech Treatment for Minimally Verbal Children With ASD and CAS
A NA study of Autism Spectrum Disorder and Developmental Verbal Dyspraxia, sponsored by MGH Institute of Health Professions.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05066178: Recruiting NA study of Autism Spectrum Disorder and Developmental Verbal Dyspraxia, sponsored by MGH Institute of Health Professions.
NCT05066178 is a NA study of Autism Spectrum Disorder and Developmental Verbal Dyspraxia that is actively recruiting participants, run by MGH Institute of Health Professions. The registered enrollment target is 20 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05066178, a NA study of Autism Spectrum Disorder and Developmental Verbal Dyspraxia, is actively recruiting participants, sponsored by MGH Institute of Health Professions.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.
Primary Outcome
Number or percent of target items that were produced correctly
Conditions Studied
Interventions
- BEHAVIORAL CAS Treatment for Minimally Verbal Children with Autism
Study Locations (1)
Massachusetts
- MGH Institute of Health Professions - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
What NCT05066178 shows while recruiting
NCT05066178 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which CAS Treatment for Minimally Verbal Children with Autism is the first listed.
NCT05066178 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05066178 about?
NCT05066178 is a clinical study titled "Speech Treatment for Minimally Verbal Children With ASD and CAS". Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with ...
What is the current status of trial NCT05066178?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-05-01. Estimated completion is 2026-11-30.
What conditions does trial NCT05066178 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Developmental Verbal Dyspraxia.
What interventions are being tested in trial NCT05066178?
The interventions under investigation include: CAS Treatment for Minimally Verbal Children with Autism (BEHAVIORAL).
Who is sponsoring clinical trial NCT05066178?
This trial is sponsored by MGH Institute of Health Professions, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05066178 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05066178's enrollment target sits among peer trials
20 200th of 224 higher than 23 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
-
Cerebellum and Autism: Regional Specialization for Social and Executive Functions
RECRUITING · NA
-
Milieu Teaching-AV (MT-AV Pilot)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI